-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 29, 2024

Potential Consequences of Early Diagnosis of Alzheimer Disease

Author(s)Derek van Amerongen, MD, MS, Soeren Mattke, MD, DSc, B. Joy Snider, MD, PhD

B. Joy Snider, MD, PhD, discusses the benefits of early diagnosis of Alzheimer disease and how it can impact the patient journey.

Episodes in this series

A panel of 5 experts on Alzheimer disease

EP. 1 The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System

B. Joy Snider, MD, PhD, and Maria Lopes, MD, MS

EP. 2 Recent Insights into the Pathophysiology of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 3 Genetic Aspects of Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 4 The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 5 Potential Consequences of Early Diagnosis of Alzheimer Disease

Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"

EP. 6 Criteria for Diagnosing Alzheimer Disease and the Role of Testing

A panel of experts on Alzheimer's disease

EP. 7 Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 8 Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

A panel of experts on Alzheimer's disease

EP. 9 Clinical Decision-Making for Alzheimer Disease Management

A panel of experts on Alzheimer's disease

EP. 10 Cost, Value, and Affordability of Treatment for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 11 Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates

A panel of 5 experts on Alzheimer disease

EP. 12 Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden

A panel of 5 experts on Alzheimer disease

EP. 13 Payer Coverage Considerations for New Treatments for Alzheimer Disease

A panel of 5 experts on Alzheimer disease

EP. 14 Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

What is the importance of early diagnosis of AD? How could this impact the patientjourney?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 25th 2026

Kerry Rogers, MD

Managing Toxicity, Sequencing for Long-Term BTKIs: Kerry Rogers, MD

ByMaggie L. Shaw,Kerry Rogers, MD

June 25th 2026

Dr Claire Harrison | Image Credit: Guy's and St. Thomas' NHS Foundation Trust

Early SENTRY Data Suggest Benefit of Selinexor-Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis: Claire Harrison, MD

ByBrooke McCormick,Claire Harrison, MD

June 25th 2026

Julie Eastland, MBA, is the CEO of Zentalis, which is advancing a next-generation WEE1 inhibitor, azenosertib. | Image: Zentalis

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF

Zanubrutinib Tops Rivals in Real-World CLL Survival Study